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Abstract: A murine monoclonal IgG1 antibody, marked as MAb26, specific for 
tetanus toxoid has been immunochemically characterized. By performing en-
zyme-linked immunosorbent assays (ELISAs) and western blot analyses, it was 
demonstrated that MAb26 reacted with tetanus toxoid, tetanus toxin and β2-gly-
coprotein I (β2GPI). According to the results, MAb26 recognized the sequential 
epitope on the tetanus heavy chain. The affinity constant, calculated from Scat-
chard plots of MAb26 binding to tetanus toxoid, was 1.145×108 M-1 and the 
measurement of the relative affinity of MAb26 by ELISA using thiocyanate 
elution showed a significantly higher affinity of MAb26 to the toxoid (p = 
= 0.0012) in comparison to the toxin. Additionally, the reactivity of MAb26 
toward the toxoid forms increased when the tetanus toxin was detoxified using 
8 mM and higher formaldehyde concentrations. The similarity of the tetanus 
toxoid to several sera proteins, either at the level of its conformation (IL-1α) or 
at the level of peptide sequences (β2GPI, laminin) favors its role in auto-
immunity by the mechanism of molecular mimicry. As the induction of an au-
toimmune disease is dependent on the breakdown of tolerance, which could be 
the result of an overt hyperstimulation, the control of the presence and concen-
tration of self-reactive epitopes in vaccine preparations is a prerequisite. In this 
study, it was shown that MAb26 can: 1) discriminate between the tetanus toxin 
and different toxoid forms, which makes it a good candidate for antibody con-
trol during vaccine preparation; 2) due to its cross-reactivity with β2GPI, it could 
provide information on the presence of a potentially dangerous sequential epi-
tope expressed at the protein surface. 
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INTRODUCTION 
Tetanus toxin (TTn) is an enormously potent neurotoxin1 secreted by the 
anaerobic soil bacterium, Clostridium tetani and is comprised of two polypeptide 
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chains, termed heavy (H, 100 kD) and light (L, 50 kD) chains, linked by a disul-
phide bond. These two chains are functionally distinct; the H chain is responsible 
for binding and cell entry, while the L chain is catalytically active and functions 
as a zinc-dependent endopeptidase. TTn traffics to the central nervous system by 
retrograde axonal transport followed by trans-synaptic spread into inhibitory in-
terneurons,2,3 where it specifically cleaves the synaptic vesicle protein synapto-
brevin. Synaptobrevin cleavage by TTn blocks the release of inhibitory neuro-
transmitters leading to spastic paralysis. In concentration of approximately 1 
ng/kg,4 TTn induces death in non-vaccinated humans. 
As TTn induces death before an adaptive immunity could be generated, ac-
tive immunization5 with tetanus vaccine (TTdV) is crucial for the prevention of 
death caused by tetanus. At present, protection is routinely induced through im-
munization with a TTn derivate, tetanus toxoid (TTd), obtained by chemical mo-
dification with formaldehyde,6 which was first described more than 80 years ago. 
TTn inactivated by formaldehyde is devoid of toxicity but is still highly immuno-
genic with a stabilized native conformation. 
The similarity between TTn and several sera proteins (β2GPI, laminin) at the 
level of short peptide sequences favors its role in autoimmunity by the mecha-
nism of molecular mimicry.7,8 This fact implies that the application of TTd re-
quires prior detailed characterization and precise quantification. The cross-reac-
tivity of TTn, especially with β2GPI drew our attention as it has been shown that 
β2GPI is a major antigen in the antiphospholipid syndrome (APS).9 
With the intent of examining further the specificity of anti-tetanus antibo-
dies, an anti-tetanus monoclonal antibody (MAb), marked as MAb26, which re-
cognizes the epitope located on both forms of tetanus: natural toxin and its che-
mical derivative, toxoid, was immunochemically characterized. In addition, MAb26 
cross-reacted with β2GPI and could be regarded as a convenient tool for an in-
vestigation related to the potential generation of some “surprising” and poten-
tially hazardous anti-β2GPI autoantibodies, possibly through the molecular mi-
micry mechanism. There is a general consensus that autoimmune diseases de-
pend on genetic and environmental factors. As studies on experimental APS mo-
dels proved that there is molecular mimicry between β2GPI-related synthetic 
peptides and structures within bacteria and viruses, TTd, might be a cause for 
experimental APS.10 Since the pathogenic potential of MAb26 in vivo has 
already been demonstrated,11 this study was conducted with the aim of further 
analyzing the immunochemical characteristics of MAb26, with the emphasis on 
the analysis of the reactivity of MAb26 toward different tetanus antigenic 
determinants. The obtained results also indicate that formaldehyde modification 
potentiates the conformational expression of β2GPI cross-reactivity. 
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EXPERIMENTAL 
Antigens 
TTn was purified from fermentation cultures of Clostridium tetani and inactivated at a 
fixed concentration of 180 Lf/ml by adding formaldehyde to final concentrations of 0, 2, 4, 8, 
16, 32, 64 and 128 mM. The mixture was adjusted to pH 7.4 and incubated at 35 °C for 4 
weeks. The resulting “detoxified samples” were then dialyzed and filtered to remove the ex-
cess of inactivation reagents. After a final pH adjustment and filtration, the samples were ali-
quoted and used in the experiments. In the following text, when the formaldehyde concen-
tration is not specifically indicated, the abbreviation TTd refers to the tetanus toxoid obtained 
using 128 mM formaldehyde. 
β2GPI was purified from normal human plasma using sequential precipitation with 
(NH4)2SO4, 65 % saturation, from the supernatant obtained following perchloric acid addition 
to human plasma (final concentration 1.75 %) and chromatographic steps (Mono S column; 
ÄKTA Purifier, Pharmacia Amersham, Uppsala, Sweden). Both Ags were checked for purity 
by SDS-PAGE (Phast System, Pharmacia Amersham, Uppsala, Sweden) and identified by im-
munoblot, using either commercially available mouse anti-human β2GPI IgG1 (IgG1; clone 
5F7, ICN Biomedicals, Aurora, USA) or anti-TTd standard antibodies. 
Production of MAbs specific for TTd 
MAbs to TTd were produced by the hybridoma technology.12 MAb26 was IgG1 which 
was demonstrated by ELISA, using commercially available biotin-labeled MAbs specific for 
mouse IgG subclasses (ICN Biomedicals, Aurora, USA) for detection. MAb26 producing hyb-
ridoma was cultured in integra bottles (Integra CL 350, Integra Biosciences, Switzerland) and 
the MAb was affinity purified from the supernatant on a Protein A-Sepharose 6B (Pharmacia 
Amersham, Uppsala, Sweden) column according to the instructions of the manufacturer. The 
purity of MAb preparations were determined by sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). The isolated MAb26 was used for F(ab’)2 and Fab’ production 
according to a procedure previously described.13 The resulting proteolytic digestion samples 
were dialyzed against 100 mM Tris-HCl buffer, pH 8.1, and intact Fc fragments and non-di-
gested antibody were removed by Protein A-Sepharose chromatography. The F(ab’)2 prepa-
ration showed a single band at 100 kD and a doublet of bands at 25 kD in non-reducing and 
reducing SDS-PAGE, respectively. The Fab’ preparation showed a single band at 50 kD and 
25 kD in non-reducing and reducing SDS-PAGE, respectively. The obtained antigen-binding 
fragments, as well as intact MAbs were biotin labeled (–B) according to a previously descri-
bed procedure.14 
Reactivity of MAb26 with TTn and TTd 
ELISA plates (MaxiSorp, Nunc) were covered (50 μl/well) with TTn or TTd (1μg 
ml-1 PBS) by overnight adsorption at 4 °C. A 1 % BSA/PBS solution was used for blocking 
non-specific binding for 2 h at room temperature). The saturation, as well as each subsequent 
ELISA step, was followed by washing with 0.05 % Tween 20/PBS (4×200 μl/well). MAb26 
(0.50–10 µg/ml) was added to the plate and incubated for 1 h at room temperature. Biotin- 
-labeled antibodies specific for mouse IgG (ICN) (50 μl/well) were incubated for 1 h at room 
temperature. The system extrAvidin-peroxidase/OPD was used for “visualization” of Ag–Ab 
interaction. The absorbance was read at 492/692 nm. 
The measurement of the relative MAb26 affinity by ELISA using thiocyanate elution 
The affinities of MAb26 to TTd and TTn were estimated by use of aqueous solutions 
containing different potassium thiocyanate (KSCN) concentrations.15 Analysis of the in-
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fluence of thiocyanate ion (SCN–) on the specific MAb26 binding was performed with ELI-
SA-based procedures. The protocol was similar to those performed for the reactivity determi-
nation of MAb26 with TTd and TTn. The single difference was an additional 1-hour incuba-
tion with aqueous KSCN solutions after the binding of MAb26 to the adsorbed Ags. Aqueous 
solutions containing increasing KSCN concentrations (0–6 M) were employed for MAb26 de-
sorption. The SCN– concentration ([SCN–]) that induced a 50 % reduction of initial absor-
bance ([SCN–]50 %) was calculated for each sample upon linearization of the corresponding 
Ag–Ab dissociation profile (Binding (%) = f([SCN–])). A preliminary experiment showed that 
KSCN in the concentrations used did not induce desorption of coated TTd or TTn. To eva-
luate the significance of the observed differences in MAb26 affinity toward TTd and TTn, 
dissociation profiles (Binding (%) = f([SCN–]) were compared by a paired Student’s t-test. 
Reactivity of MAb26 with TTn adsorbed onto gangliosides 
ELISA plates (PolySorp, Nunc) were covered (50 μl/well) with the appropriate gang-
lioside: GT1b or GD1b (10 μg/ml in methanol) by overnight evaporation at room temperature. 
A 1 % BSA/PBS solution was used for saturation for 2 h at room temperature. The saturation, 
as well as each subsequent ELISA step, was followed by washing with PBS (4×200 μl/well). 
TTn/1 % BSA (20 µg /ml) or 1 % BSA were added to the plate and incubated for 1 h at 37 °C. 
MAb26 (10 µg/ml) or TTd-specific mouse anti-serum (polyclonal anti-TTd Abs, 1:400) were 
added to the plate and incubated for 1 h at 37 °C. After washing, the biotin-labeled antibodies 
specific for mouse IgG (ICN) was added to the plate (50 μl/well). System extrAvidin-pe-
roxidase/OPD was used for “visualization” of the Ag–Ab interaction. The absorbance was 
read at 492/692 nm. 
SDS-PAGE and Western blot 
TTn, TTd and β2GPI were resolved by SDS-PAGE on 1-mm-thick 9 % separating gels, 
with 4 % stacking gels (Mini Protean II System, Bio-Rad, USA). The proteins were electro-
phoretically transferred to PVDF membranes (Millipore Corporation, Bedford, MA, USA) for 
1 h at 4 °C and 1–1.5 mA/cm2 (Multiphor II System, LKB, Sweden) in buffer containing 25 
mM Tris (Pharmacia), 193 mM glycine (Pharmacia), and 15 % methanol (Fluka). To prevent 
non-specific antibody binding, the membranes were incubated with blocking buffer, 3 % BSA 
(Sigma) in PBS for 2 h. MAb26 was diluted in blocking buffer and the incubations were per-
formed for 1 h at room temperature. The membranes were incubated with anti-mouse IgG-B 
(Sigma) diluted 1:5000, followed by streptavidin–phosphatase (Sigma) diluted 1:1000. The 
membranes were washed three times with 0.05 % Tween 20 (Sigma)/PBS and twice with PBS 
after the incubations. The antibody binding was visualized by exposure to 5-bromo-4-chloro-
3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) (Bio-Rad). 
SDS-PAGE under reducing conditions was performed similarly to that described above 
with the following differences: 1) the proteins were resolved by electrophoresis on a gradient 
4.0–15 % polyacrylamide gel (Pharmacia) and 2) the samples contained 5 % 2-mercapto-
ethanol. 
Reactivity of MAb26 with β2GPI 
ELISA plates (MaxiSorp, Nunc) were covered (50 μl/well) with β2GPI (10 μg/ml 
β2GPI/PBS) by overnight adsorption at 4 °C. A 1 % BSA/PBS solution was used for satu-
ration for 2 h at room temperature. The saturation, as well as each subsequent ELISA step, 
was followed by washing with 0.05 % Tween 20/PBS (4×200 μl/well). MAb26 (0.50–10 
µg/ml) was added to the plate and incubated for 1 h at room temperature. The biotin-labeled 
antibodies specific for mouse IgG (ICN) (50 μl/well) were incubated for 1 h at room tem-
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perature. The system extrAvidin-peroxidase/OPD was used for “visualization” of the Ag–Ab 
interaction. The absorbance was read at 492/692 nm. 
Competitive inhibition ELISA: binding of MAb26 for β2GPI in the presence of differently 
detoxified forms of TTn 
The β2GPI was bound to the MaxiSorp (Nunc) microtiter plates by overnight adsorption 
at 4 °C, at a concentration of 10 µg/ml. Detoxified samples (20 µg/ml), made by adding for-
maldehyde to final concentrations of 0, 2, 4, 8, 16, 32, 64 and 128 mM, were mixed with 
F(ab’)2 MAb26, 10 µg/ml, then pre-incubated for 1 h at 25 °C in a water bath and further in-
cubated with β2GPI coated on the microplate walls. ExtrAvidin-peroxidase/OPD was used as 
the detection system. The percentage binding (BI) was calculated after determination of the 
free MAb26 from the standard curve A492/692 = f((F(ab’)2MAb26)). 
Double immunodiffusion 
Double immunodiffusion16 was performed for subclass determination and for the detec-
tion of the precipitating properties of MAb26. 
RESULTS AND DISCUSSION 
Preliminary tests, performed with supernatants of hybridoma 26, indicated 
that MAb26 reacts with TTd, TTn and β2GPI. The hybridoma 26, secreting 
MAb26 of the IgG1 subclass (pI 7.4), was further subcloned, propagated in In-
tegra bottles and characterized. Although this characterization included the con-
ventional approach to study MAbs, the focus was on the investigation of the un-
usual binding features of MAb26, the localization of its partial epitope and po-
tential applications. 
Binding properties of MAb26 
The reactivity of the isolated MAb26 toward TTd and TTn was tested using 
direct ELISA and this MAb displayed strong reactivity toward tetanus antigenic 
determinants. The reactivity pattern undoubtedly demonstrated anti-TTd binding 
specificity with a Ka value of 1.145×108 M–1, determined for isolated TTd (150 
kD) in competitive ELISA (Fig. 1a). The reactivity toward TTd was higher in 
comparison to the reactivity toward TTn, which was confirmed by analysis of the 
influence of KSCN on MAb26 binding to TTd and TTn (Fig. 1b). Significant dif-
ferences between the elution profiles of MAb26 from TTn and TTd following 
incubation with KSCN in various concentration were revealed by paired Stu-
dent’s t-test (p = 0.0012), indicating a large difference in the affinity of MAb26 
toward these antigens. The calculated [SCN–]50 % values confirmed the higher af-
finity of MAb26 toward TTd compared to TTn. Parallel binding curves of MAb26 
and its F(ab’)2 and Fab’ fragments for TTd or TTn revealed the same binding 
pattern, which excluded the necessity of bivalent binding of MAb26 (Fig. 2), 
which is in accordance with the high affinity of MAb26 toward these Ags. 
The MAb26 was also reacted with β2GPI. It was not possible to calculate the 
affinity of MAb26 toward β2GPI by the standard Scatchard method. The first 
reason could be its low affinity toward β2GPI and the second, probably more im- 
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portant, is the requirement of its bivalent binding.17 The necessity to use a high 
concentration of β2GPI (10 µg/ml) for the detection of MAb26 binding implies a 
low affinity of MAb26 toward β2GPI (Fig. 3a). Bivalent binding of MAb26 to 
β2GPI could explain the non-linear dependence of MAb26 binding to β2GPI 
following its incubation with solutions containing different concentration of 
KSCN and the relatively high value of [SCN–]50 % (Fig. 3b). Finally, as was 
shown in a previous study,11 the absence of Fab’ binding to β2GPI adsorbed in a 
concentration which allows the detection of MAb26, but the presence of binding 
 
(a) 
(b) 
Fig. 1. a) Scatchard plot (B/F = f(B)) of 
the binding of MAb26 to TTd measured 
by ELISA at 25 °C, B – concentration of 
MAb26 bound to TTd, F – concentration 
of free MAb26, and b) measurement of 
the relative affinity of MAb26 toward TTn 
and TTd by ELISA using thiocyanate 
elution. The corresponding [SCN-]50 % va-
lues are indicated within the graph. 
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of intact MAb26 and its F(ab’)2 to β2GPI, confirmed the requirement of bivalent 
binding of MAb26 to β2GPI. 
 
Fig. 2. Binding curves of MAb26 and its F(ab’)2 and Fab’ fragments to TTd and TTn. 
Partial characterization of the MAb26 binding epitope 
Western blot revealed that MAb26 recognized the band of 150 kD in TTd/ 
/TTn and cross-reacted with β2GPI (Fig. 4a). These results suggest that the epi-
tope recognized by MAb26 was most probably sequential and not dependent on 
the native structure of TTd/TTn or β2GPI. Further Western blot experiments per-
formed after SDS-PAGE obtained under reducing conditions revealed that MAb26 
binding epitope most probably lies on the tetanus heavy chain (Fig. 4b). 
The reactivity of MAb26 toward different detoxified samples, made by ad-
ding formaldehyde to final concentrations of 0, 2, 4, 8, 16, 32, 64 and 128 mM, 
was tested by ELISA. It could be seen (Fig. 5) that the reactivity of MAb26 in-
creased when the Ags were used in which the TTn had been detoxified using 8 mM 
and higher formaldehyde concentrations. A similar MAb26 binding pattern was 
revealed by Western blot (Fig. 6b) performed after SDS-PAGE obtained under 
reducing conditions with detoxified samples (Fig. 6a). 
The results of MAb26 binding to TTn adsorbed directly onto a microtiter 
plate or a microtiter plate pre-coated with gangliosides supported the hypothesis 
that the epitope recognized by MAb26 is located on the H chain of the TTn/TTd 
molecule. The gangliosides (GD1b and GT1d) represent natural receptors for TTn 
and the ganglioside binding site is located on the C-terminal domain of the H 
chain of TTn. It was shown (Fig. 7) that adsorption of TTn to gangliosides almost 
completely inhibited its recognition by MAb26, most probably due to steric hin-
drance.18 
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(a) 
(b) 
Fig. 3. a) Binding curve of MAb26 to in-
creased β2GPI concentrations adsorbed onto a 
MaxiSorp microtiter plate and b) measu-
rement of the relative affinity of MAb26 to-
ward β2GPI by ELISA using thiocyanate elu-
tion. The corresponding [SCN–]50 %  values 
are indicated within the graph. 
The observed differences in reactivity of MAb26 toward the different toxoid 
forms might be the result of the different extent of chemical modification and this 
fact could eventually be used for discrimination between TTn and the toxoid 
forms or to confirm the efficient transformation of TTn to toxoid forms. 
Cross-reactivity of MAb26 with β2GPI 
By using “detoxified TTd samples” as inhibitors of MAb26–β2GPI binding, 
an attempt was made to evaluate whether the formaldehyde concentration used in 
the detoxification process could have any impact on the structure of the β2GPI-like 
epitope on the TTd molecule. It is evident that the β2GPI-like epitope was pre-
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sent in the TTn molecule and was potentiated through conformational changes in-
duced by formaldehyde treatment. A 50 % inhibition of binding F(ab’)2 MAb26 
to β2GPI was obtained in the presence of as little as 4 mM formaldehyde in the 
TTn detoxification process (Fig. 8). This result could favor the possibility that the 
native conformation is stabilized by the formaldehyde-induced cross-links. 
 
 (a)  (b) 
Fig. 4. a) SDS-PAGE of TTd (lane 2), β2GPI (lane 4) and TTn (lane 6) on a 9 % polyacryl-
amide gel and Western blot analysis of MAb26 TTd (lane 3), β2GPI (lane 5) and TTn (lane 7). 
The molecular weight marker kit (lane 1) consisted of myosin (212 kD), α-macroglobulin 
(170 kD), β-galactosidase (116 kD), transferrin (76 kD) and glutamic dehydrogenase 
(53 kD), (b) SDS-PAGE of TTd under reducing conditions and Western blot analysis. 
 
Fig. 5. Binding of MAb26 to different detoxified samples (made by adding formaldehyde to 
final concentrations of 0, 2, 4, 8, 16, 32, 64 and 128 mM) immobilized directly onto 
a UV-irradiated MaxiSorp plate. All the samples were assayed in triplicate 
and the mean ±SD are presented. 
2009 Copyright (CC) SCS254 INIĆ-KANADA et al. 
 
 (a)  (b) 
Fig. 6. SDS-PAGE of detoxified samples (with 0, 4, 8, 32 and 64 mM formaldehyde) under 
reducing conditions on a gradient 4–15 % PAG (a) and Western blot analysis 
of former samples 1–4 with MAb26 as 5–8, respectively (b). 
 
Fig. 7. Binding of MAb26 to TTn, gangliosides and TTn + gangliosides. 
Polyclonal anti-TTd anti-serum was used as the positive control. 
MAb26 is cross-reactive with β2GPI and might be employed as a convenient 
tool for investigations related to the potential generation of anti-β2GPI autoanti-
bodies, possibly by the molecular mimicry mechanism. The theory of molecular 
mimicry, one of the mechanisms thought to be responsible for the association of 
autoimmunity with infections, involves the display of epitopes resembling the 
host determinants by the infectious agent. The epitope of a pathogen may induce 
an immune response that breaks down self-tolerance by cross-reactivity, thus in-
ducing an auto-immune response leading to disease. The involvement of mole-
cular mimicry and immunization with TTd in the induction of APS was demon-
strated in experimental animal models.19–21 In a previous study,11 experimental 
APS in BALB/c mice (which are not lupus-prone, i.e. the mice were not geneti-
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cally predisposed to autoimmune diseases) was induced after they had been pas-
sively infused with MAb26. 
 
Fig. 8. Inhibition of MAb26 binding to β2GPI in the presence of 
differently detoxified forms of TTn. 
As the induction of autoimmune disease is dependent on the breakdown of 
tolerance, which could be the result of overt hyperstimulation, control of the pre-
sence and concentration of self-similar epitopes in vaccine preparations is a pre-
requisite. This favors MAb26 as a valuable tool in the preparation process of a 
tetanus toxoid vaccine. 
Precipitating properties of MAb26 
In addition to the characterization of MAb26, it was shown that this MAb 
precipitated TTd and TTn in solution and also exhibited good precipitating pro-
perties in gels, as demonstrated by double immunodiffusion (Figs. 9a and 9b). 
 
Fig. 9. Double immunodiffusion of MAb26 against TTd, TTn and β2GPI performed in a 1.0 
% agarose gel. TTd (a), TTn (b) and β2GPI (c) were placed in the central wells at a con-
centration of 1.0 mg/ml. The concentrations of MAb26 that were placed in the 
peripheral wells were 2-fold dilutions starting with 0.50 (well 1), 0.25 (well 2), 
0.125 (well 3), 0.0625 (well 4), 0.03125 (well 5) and ending with 0.015 mg/ml (well 6). 
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Although MAb26 could not precipitate β2GPI in solution which is in accordance 
with data from the literature for anti-β2GPI Abs, MAb26 exhibited good precipi-
tating properties in gels (Fig. 9c). 
CONCLUSIONS 
According to the presented results, it can be concluded that the characterized 
MAb26 could be employed as a control antibody during vaccine preparation. Its 
different affinities toward tetanus toxin and toxoid might be used for following-up 
the detoxification process, which is indispensable for vaccine production. On the 
other hand, the cross reactivity with β2GPI could expand the information of the 
presence of a potentially dangerous sequential epitope expressed at the protein 
surface after detoxification. 
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ИЗВОД 
МОНОКЛОНСКО АНТИТЕЛО 26 НАПРАВЉЕНО НА ТЕТАНУС ТОКСОИДУ РЕАГУЈЕ И 
СА ТЕТАНУС ТОКСИНОМ И β2-ГЛИКОПРОТЕИНОМ I – КАРАКТЕРИСТИКЕ 
ВЕЗИВАЊА IN VITRO И МОГУЋА ПРИМЕНА 
АЛЕКСАНДРА Б. ИНИЋ-КАНАДА, МАРИЈАНА М. СТОЈАНОВИЋ, ИРЕНА П. ЖИВКОВИЋ, 
ВЛАДИМИР Ж. ПЕТРУШИЋ и ЉИЉАНА ДИМИТРИЈЕВИЋ 
Institut za virusologiju, vaccine i serume “Torlak”, Vojvode Stepe 458, 11152 Beograd 
Oвај рад описује имунохемијску карактеризацију мишјег IgG1 моноклонског антитела 
oзначеног као МАт26. Ензимским имуносорбентним тестом (ЕLISA) и Western blot анализом 
је показано да МАт26 реагује са тетанус токсоидом, тетанус токсином и β2-гликопротеином I 
(β2GPI). Према нашим резултатима, МАт26 препознаје секвенциони епитоп на тешком ланцу 
молекула тетануса. Константа афинитета МАт26 за тетанус токсоид, израчуната на основу 
Скачардовог дијаграма, је 1,145×108 M-1. На основу елуције тиоцијанатом, коришћене за од-
ређивање релативног афинитета МАт26 за тетанус токсин и тетанус токсоид, поступком ба-
зираним на ЕLISA-и, показан је знатно већи (p = 0,0012) афинитет МАт26 ка токсоидној 
форми. Такође, реактивност МАт26 ка токсоидној форми расла је са порастом концентрације 
формалдехида, почевши од 8 mМ, коришћеног у процесу детоксификације. Сличност тета-
нус токсоида са различитим серумским протеинима на нивоу конформације и/или пептидних 
секвенција (β2GPI, ламинин) указује на његову потенцијалну улогу у индукцији аутоиму-
ности механизмом молекулске мимикрије. Будући да настанак аутоимунске болести под-
разумева  нарушавање  толеранције,  на  пример,  прекомерном  стимулацијом  имунског сис-
тема, контрола присуства и концентрације себи сличних епитопа се намеће као неопходна. У 
овом  раду  је  показано  да: 1) МАт26  може  да  прави  разлику  између  тетанус  токсина  и 
различитих  токсоидних  форми  што  га  чини  потенцијално  добрим  антителом  које  би  се 
користило у контроли током производње вакцина; 2) захваљујући унакрсној реактивности са 
β2GPI, МАт26 може да пружи информације о присуству потенцијално опасних епитопа на 
површини протеина. 
(Примљено 17. јула, ревидирано 7. новембра 2008) 
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